Reply to: “Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study” and “TRIPLETE But Incomplete? Accounting for Postprogression Therapy When Interpreting Overall Survival”

Veronica Conca

Veronica Conca, MD, PhD, Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy; Daniele Rossini, MD, PhD, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and Chiara Cremolini, MD, PhD, Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy

Daniele Rossini

Chiara Cremolini